SCHEMBL2094620

SCHEMBL2094620

CCC(C)Oc1ccccc1NC([O])=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.51
KDM4E B2RXH2 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
TSHR P16473 2/20 0.47
GAA P10253 1/20 0.45
RAB9A P51151 2/20 0.44
MEN1 O00255 2/20 0.44
POLB P06746 1/20 0.43
EBP Q15125 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
NPC1 O15118 1/20 0.43
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP2C19 P33261 1/20 0.41
HPGD P15428 1/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9803560 0.88 HSD17B10 (0.56) KMT2AKDM4EL3MBTL1TSHRRAB9A
SCHEMBL2089674 0.84 KMT2A (0.48) KMT2AKDM4EL3MBTL1TSHRGAA
SCHEMBL2088830 0.83 ALDH1A1 (0.51) KMT2AKDM4EL3MBTL1POLBHTT
SCHEMBL11777237 0.80 ALDH1A1 (0.53) KMT2AKDM4EL3MBTL1TSHRGAA
SCHEMBL2096191 0.76 KMT2A (0.39) KMT2AKDM4EL3MBTL1TSHRRAB9A
SCHEMBL21110674 0.76 IRAK4 (0.49) KMT2AKDM4EL3MBTL1TSHRMEN1
SCHEMBL31490284 0.75 MCHR1 (0.51) KMT2ATSHRMEN1MTNR1AMTNR1B
SCHEMBL11122433 0.75 LMNA (0.51) KMT2AKDM4EL3MBTL1RAB9AMEN1
SCHEMBL2093160 0.74 ALDH1A1 (0.62) KMT2AL3MBTL1GAARAB9AMEN1
SCHEMBL2093372 0.74 ALDH1A1 (0.48) KMT2AKDM4ETSHRRAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 KMT2A 3324/4885KDM4E 4578/4885L3MBTL1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.